Prolgolimab Monotherapy or in Combination With Bendamustine for r/r Classical Hodgkin Lymphoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 19, 2023

Primary Completion Date

March 10, 2024

Study Completion Date

March 10, 2025

Conditions
Hodgkin Lymphoma
Interventions
DRUG

Prolgolimab

Prolgolimab monotherapy 1 mg/kg IV every 2 weeks up to a maximum of 24 cycles

DRUG

Combination with prolgolimab and bendamustine

Prolgolimab 1 mg/kg IV D1,15; Bendamustine 90 mg/m2 IV D1,2, 28-day cycle, maximum of 3 cycles;

Trial Locations (2)

197022

RECRUITING

St. Petersburg State Pavlov Medical University, Saint Petersburg

Unknown

RECRUITING

N.N. Petrov National Medical Research Center of Oncology, Saint Petersburg

All Listed Sponsors
collaborator

N.N. Petrov National Medical Research Center of Oncology

OTHER

lead

St. Petersburg State Pavlov Medical University

OTHER